Calgary, Alberta – TheNewswire - January 3, 2024 – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) is pleased to update the Corporation’s business operations and explain its business model.

 

Introduction: In addressing the pressing challenges of the mental health crisis, nDatalyze presents a revolutionary solution – the YMI clinical decision support system, an advanced data analysis tool that represents a fundamental change to the way mental conditions are diagnosed and treated. This transformative tool aims to substantially improve both mental health diagnosis rates and treatment, thereby helping elevate overall societal mental health. The following outlines the strategic approach that underlies YMI’s business model.

 

The Problem: As published in the National Library of Medicine (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/), between 2011 and 2030, the cumulative economic output loss associated with mental disorders is projected to be US$ 16.3 trillion worldwide, making the economic output loss related to mental disorders comparable to that of cardiovascular diseases, and higher than that of cancer, chronic respiratory diseases, and diabetes. Unfortunately, current mental condition diagnostic methods are wrong over half the time; essentially a coin toss that is often followed by inappropriate drug prescriptions with poor results and unwanted side effects. This prevalent "trial-and-error" approach hinders patient well-being, congests mental health systems, and contributes to an overall decline in societal mental health.

 

YMI Solution: YMI addresses the root causes of misdiagnosis by leveraging an objective, fact-based Reference Database and clinician-guided machine-learning algorithms. This approach replaces subjective patient opinions with well-informed diagnostic predictions that are consistent, rapid, and less biased; fundamentally altering the diagnostic and treatment landscape.

 

Strategic Approach with a Three-Step Strategy: YMI's evolution involves three crucial steps – 1. creating the system, 2. establishing credibility through clinical studies, and 3. penetrating the market through a series of relationships. We have already completed Step 1 – YMI is fully functional and online today.

 

Step 2 - Clinical Studies for Credibility: Ongoing studies to involve the Canadian Mental Health Association, and renowned professionals, Dr. Andrew Greenshaw, Dr. Bo Cao, and Dr. Dale Stevens, aim to validate YMI's effectiveness and explore the benefits of DNA data integration.​ News release references are:    

Dec 21, 2023 https://quotemedia.com/portal/quote?qm_symbol=NDAT%3ACNX&qmodStoryID=5772724448358146  

Dec 18, 2023 https://quotemedia.com/portal/quote?qm_symbol=NDAT%3ACNX&qmodStoryID=8848133407154159  

Nov 14, 2023 https://quotemedia.com/portal/quote?qm_symbol=NDAT%3ACNX&qmodStoryID=5541047718403320

Step 3 - Market Penetration: To become the preferred mental condition diagnostic tool across Canada and the US, YMI aims to forge relationships with governmental health authorities and health insurance companies, as is evident in recent news releases.

 

Revenue Generation: Usage Fees and Licensing: nDatalyze anticipates recurring revenue through usage fees for each YMI system use, and/or licensing agreements. Target markets include governmental health care systems, private health care insurers, risk-based businesses like insurance companies, airlines, police & security, and trucking/shipping industries.

 

Capital Sufficiency: The corporation has ample capital to fund ongoing studies.

 

Reporting: Preliminary results from clinical studies are expected within the next 120 days, with updates on the progress thereafter.

 

About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time, and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual’s predisposition toward a variety of common mental conditions, both current and forward in time.

 

nDatalyze's YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns both societal impact and financial success.

 

For Further Information, Please Contact:

 

Dr. Keith Courtney, President (psychiatric aspects)

Email: drkeithcourtney@gmail.com

or

James Durward, CEO&CTO (technical aspects)

Email: jimd@ndatalyze.com    

nDatalyze Website: https://www.ndatalyze.com      

YMI Website: https://ymihealth.ca

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

 

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.